Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

Cancer is still the leading cause of death globally. The approval of the therapeutic use of monoclonal antibodies against immune checkpoint molecules, notably those that target the proteins PD-1 and PD-L1, has changed the landscape of cancer treatment. In particular, first-line PD-1/PD-L1 inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Marei, Hany E., Hasan, Anwarul, Pozzoli, Giacomo, Cenciarelli, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088229/
https://www.ncbi.nlm.nih.gov/pubmed/37038154
http://dx.doi.org/10.1186/s12935-023-02902-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088229/
https://www.ncbi.nlm.nih.gov/pubmed/37038154
http://dx.doi.org/10.1186/s12935-023-02902-0

Ejemplares similares